Otsuka Pharmaceutical
Otsuka Pharmaceutical Co., Ltd. is a major Japanese healthcare and pharmaceutical company founded in 1921 and headquartered in Tokyo. The company operates globally across three key areas: pharmaceuticals, clinical nutrition and IV solutions, and nutraceuticals. Its pharmaceutical business focuses on areas such as central nervous system disorders, oncology, and cardiovascular and renal diseases, while its nutraceutical portfolio includes well-known products such as Pocari Sweat and Calorie Mate. Through Otsuka Pharmaceutical India Private Limited, the company also has a presence in India, particularly in intravenous infusion and clinical nutrition products, supported by a manufacturing facility near Ahmedabad, Gujarat. Its clinical nutrition and medical solutions business is primarily driven by Otsuka Pharmaceutical Factory.
Otsuka Pharmaceutical, through its subsidiary Otsuka America, completed the acquisition of Transcend Therapeutics for $700 million upfront, with up to $525 million in milestone payments, bringing the total deal value to $1.225 billion. The acquisition adds Transcend’s lead candidate, TSND-201 (methylone), a rapid-acting neuroplastogen being developed for post-traumatic stress disorder (PTSD), to Otsuka’s central nervous system portfolio.
“Otsuka strengthens its CNS portfolio with a potential $1.225 billion acquisition, adding Transcend’s promising rapid-acting PTSD therapy."
Methylone (TSND-201)
Mechanism of Action: Dopamine release stimulants; Serotonin release stimulants Drug Class: Small molecules Originator: Transcend Therapeutics Indication: Post-traumatic stress disorders
TSND-201 (methylone) is a short-acting, non-hallucinogenic neuroplastogen being developed by Transcend Therapeutics for PTSD. It acts on serotonin, norepinephrine, and dopamine transporters to promote monoamine release and enhance neuroplasticity, with potential for use alongside existing treatments such as SSRIs. Its mild, short-lived effects may also reduce clinical monitoring requirements compared with traditional psychedelics.
Otsuka Pharmaceutical-Transcend Therapeutics
Type: Merger and acquisition
Focus: TSND-201
Deal value: $1.225 billion
Financial impact: The deal adds Transcend’s lead asset, TSND-201 (methylone), a rapid-acting, non-hallucinogenic neuroplastogen for PTSD, strengthening Otsuka’s position in neuropsychiatry and advancing safer alternatives to traditional psychedelics.
Otsuka Holdings- Pharmaceutical Segment Revenue Trend, 2020–2025
Otsuka Holdings’ dedicated pharmaceutical segment showed overall strong growth over 2020–2025, with revenue increasing from $8.95 billion in 2020 to $15.51 billion in 2025, despite some year-to-year fluctuations. Revenue remained broadly stable in 2021 before rising sharply to $13.5 billion in 2022 and $14 billion in 2023. It then declined to $11.7 billion in 2024, before rebounding strongly to a six-year high of $15.51 billion in 2025, representing a 32.6% year-on-year increase. The recovery reflects the continued strength of Otsuka’s pharmaceutical portfolio, particularly in areas such as psychiatry and neurology, oncology, autoimmune diseases, and rare diseases. Otsuka reported ¥1,744.2 billion in pharmaceutical-business revenue in 2025, underscoring the segment’s role as a major growth engine for the group.
"Otsuka’s pharmaceutical business rebounded sharply in 2025, reaching a six-year revenue high and reinforcing its position as the group’s key growth driver."
Six-year market revenue of Otsuka Holding's Pharmaceutical segment (2020-2025)
Fig 9: Market revenue of Otsuka Holding's Pharmaceutical segment
Otsuka Pharmaceuticals R&D Pipeline: Delivering Innovation Across Multiple Therapeutic Areas
Otsuka Pharmaceuticals Oncology Pipeline Overview
Otsuka Pharmaceuticals maintains a diverse oncology pipeline spanning hematologic malignancies and solid tumors, with a strong focus on targeted therapies, epigenetic agents, and immuno-oncology combinations. The portfolio includes both wholly owned programs and strategic partnerships with companies such as Arcus Biosciences, Haihe Biopharma, Bristol Myers Squibb, and PharmaMar.
In hematology, Otsuka is advancing INQOVI®/INAQOVI® (decitabine + cedazuridine, ASTX727) and ASTX030 (azacitidine + cedazuridine), oral DNA methyltransferase inhibitor combinations for myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML). While INQOVI has already secured approval for AML in the US and Europe, ASTX030 is progressing through Phase III development in the US, highlighting the company's commitment to improving convenient oral treatment options for blood cancers.
In solid tumors, Otsuka's targeted therapy portfolio is led by LYTGOBI® (futibatinib, TAS-120), an FGFR inhibitor being evaluated across breast, urothelial, biliary tract, pancreatic, and esophageal cancers. Additional precision oncology assets include vepafestinib (TAS0953), a RET inhibitor; zipalertinib (TAS6417), an EGFR inhibitor in Phase III and regulatory filing stages for NSCLC; and TAS-117, an AKT inhibitor targeting tumors with germline PTEN mutations. Several earlier-stage assets, including TAS0728, TAS3351, TAS0612, and TAS2940, further strengthen the company's pipeline in molecularly defined cancers.
Otsuka is also expanding its immuno-oncology presence through collaborations with Arcus Biosciences. Key programs include zimberelimab (AB122), an anti-PD-1 antibody, as well as combination regimens with domvanalimab (AB154), an anti-TIGIT antibody, and quemliclustat (AB680), a CD73 inhibitor. Several of these programs are in Phase III development for indications such as NSCLC, upper gastrointestinal cancers, biliary tract cancer, renal cell carcinoma, and pancreatic ductal adenocarcinoma.
Overall, Otsuka's oncology strategy emphasizes oral therapies, biomarker-driven targeted treatments, and combination immunotherapy approaches, with multiple late-stage assets positioned to support future growth in both hematologic and solid tumor oncology markets.
Otsuka Psychiatry & Neurology Pipeline: Advancing Innovation in CNS and Neurodegenerative Disorders
Otsuka Pharmaceuticals is advancing a robust Psychiatry & Neurology pipeline focused on addressing significant unmet needs across schizophrenia, ADHD, anxiety disorders, PTSD, ALS, and neuromuscular diseases. The portfolio combines novel mechanisms of action, long-acting formulations, digital therapeutics, and strategic partnerships to expand treatment options in central nervous system (CNS) disorders.
Key late-stage assets include REXULTI®/RXULTI® (brexpiprazole), being developed as a once-weekly oral treatment and depot injection for schizophrenia, and centanafadine (EB-1020), a triple reuptake inhibitor for ADHD that has been filed in the US and is progressing through Phase II/III studies in Japan and China. Otsuka is also advancing ulotaront (SEP-363856), a first-in-class TAAR1 and 5-HT1A agonist licensed from Sumitomo Pharma, for schizophrenia and generalized anxiety disorder.
Beyond psychiatry, the company is expanding into neurological and rare diseases with ulefnersen (ION363) for amyotrophic lateral sclerosis (ALS), pizuglanstat (TAS-205) for Duchenne muscular dystrophy, and TSND-201 (methylone) for post-traumatic stress disorder (PTSD). Complementing its pharmaceutical portfolio, Otsuka is developing ONB-01, a Software as a Medical Device (SaMD) platform for PTSD, highlighting its commitment to integrating digital health solutions into neuropsychiatric care.
Overall, Otsuka's Psychiatry & Neurology strategy emphasizes innovative CNS mechanisms, patient-centric treatment approaches, and a balanced mix of in-house and partnered assets across both psychiatric and neurological disorders.
Otsuka Autoimmune Pipeline: Advancing Precision Therapies for Immune-Mediated Diseases
Otsuka Pharmaceuticals is building a focused autoimmune and immunology pipeline centered on innovative biologics, immune-modulating therapies, and regenerative medicine approaches. The portfolio targets a range of autoimmune and inflammatory disorders, including IgA nephropathy, Sjögren’s disease, rheumatoid arthritis, chronic spontaneous urticaria, and type 1 diabetes.
The leading asset is VOYXACT® (sibeprenlimab, VIS649), an anti-APRIL monoclonal antibody that has been approved in China for IgA nephropathy and is currently in Phase III development in Japan and Europe, while also being evaluated for Sjögren’s disease in the US. Otsuka is further strengthening its immunology pipeline through early-stage programs such as VIS171, a modified IL-2 molecule designed to selectively expand regulatory T cells, and CAN10, an anti-IL-1RAP monoclonal antibody licensed from Cantargia.
In addition, TAS5315, an oral BTK inhibitor, is advancing in Phase II studies for rheumatoid arthritis and chronic spontaneous urticaria, while OPF-310, an encapsulated porcine islet cell therapy, explores a novel regenerative approach for type 1 diabetes. Together, these programs reflect Otsuka’s strategy to deliver targeted, disease-modifying treatments that address the underlying mechanisms of autoimmune disorders and improve long-term patient outcomes.
Otsuka Diverse Disease Pipeline: Expanding Innovation Beyond Core Therapeutic Areas
Otsuka Pharmaceuticals is advancing a diversified pipeline across infectious diseases, dermatology, ophthalmology, rare metabolic disorders, urology, nutrition, and kidney disease. This broad portfolio reflects the company's commitment to addressing unmet medical needs through a combination of innovative in-house research and strategic partnerships.
Key late-stage programs include Deltyba® (delamanid) and quabodepistat (OPC-167832), both in Phase III development for multidrug-resistant tuberculosis, reinforcing Otsuka's long-standing leadership in infectious diseases. In rare diseases, repinatrabit (JNT-517) is progressing through Phase III trials for phenylketonuria, while 4D-150, a licensed ophthalmic gene therapy for neovascular age-related macular degeneration, is also in Phase III development in Japan.
The pipeline further includes Marezerto® (difamilast) for atopic dermatitis and Mikeluna® (carteolol/latanoprost) for glaucoma and ocular hypertension, both currently under regulatory review in China. Additional programs include TAC-302 for bladder dysfunction, EN-P11 for enteral nutrition management, and NO-13065 for kidney disease. Collectively, these assets demonstrate Otsuka's strategy of leveraging scientific innovation across a wide range of therapeutic areas to improve patient outcomes and support long-term growth.
